Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

✍ Scribed by Ohno, S.; Chow, L. W. C.; Sato, N.; Masuda, N.; Sasano, H.; Takahashi, F.; Bando, H.; Iwata, H.; Morimoto, T.; Kamigaki, S.; Nakayama, T.; Nakamura, S.; Kuroi, K.; Aogi, K.; Kashiwaba, M.; Yamashita, H.; Hisamatsu, K.; Ito, Y.; Yamamoto, Y.; Ueno, T.; Fakhrejahani, E.; Yoshida, N.; Toi, M.

• Book ID: 121606139
• Publisher: Springer US
• Year: 2013
• Tongue: English
• Weight: 352 KB
• Volume: 142
• Category: Article
• ISSN: 0167-6806
• DOI: 10.1007/s10549-013-2691-y